ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics.

The move enhances PLG's capabilities in drug development, focusing on reducing risk, costs and timelines while improving patient safety through advanced analyses.

Founded in Switzerland in 2015, IntiQuan is a provider of pharmacometric and statistical modelling and simulation services.

The acquisition by PLG adds valuable expertise to its portfolio, supporting biopharmaceutical companies in drug development.

It brings advanced dose-response analyses and predictive safety profiling to PLG's offerings.

PLG CEO Xavier Duburcq stated: “We are excited to welcome the IntiQuan team to PLG. They are a very strong fit with our expertise-driven organisation. Their deep and highly specialised scientific knowledge in pharmacometrics and clinical pharmacology means that we will enhance the support we provide to our clients in their drug development journey.

“Pharmacometrics and model-informed drug development offer regulatory grade insights that can impact key decision-making and accelerate clinical development, even eliminating the need for certain trials, in some cases.”

IntiQuan's addition allows PLG to offer pharmacokinetics/ pharmacodynamics, strategic consulting, population pharmacokinetics and biosimulation services.

The company’s scientific experts use mathematical modelling and simulation to inform and predict clinical trial outcomes.

The acquisition marks a significant step in PLG's strategy to build an integrated global platform for drug development services.

With plans for further expansion in the US and European markets, PLG is positioning itself as a leading global provider in this field.

IntiQuan founder Dr Henning Schmidt said: “Joining forces with PLG is a pivotal moment for IntiQuan. Our teams support IntiQuan’s clients bringing breakthrough medicines to patients and reducing both time to market and the cost of research and development through our combined solutions.”